Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
Plasma acylcarnitines and gut-derived aromatic amino acids as sex-specific hub metabolites of the human aging metabolome.
Sol J, Obis È, Mota-Martorell N, Pradas I, Galo-Licona JD, Martin-Garí M, Fernández-Bernal A, Ortega-Bravo M, Mayneris-Perxachs J, Borrás C, Viña J, de la Fuente M, Mate I, Biarnes C, Pedraza S, Vilanova JC, Brugada R, Ramos R, Serena J, Ramió-Torrentà L, Pineda V, Daunis-I-Estadella P, Thió-Henestrosa S, Barretina J, Garre-Olmo J, Portero-Otin M, Fernández-Real JM, Puig J, Jové M, Pamplona R. Sol J, et al. Aging Cell. 2023 Jun;22(6):e13821. doi: 10.1111/acel.13821. Epub 2023 Mar 23. Aging Cell. 2023. PMID: 36951231 Free PMC article.
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC. Villar LM, et al. Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30. Ann Neurol. 2015. PMID: 25581547
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.
Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study. Villoslada P, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26405686 Free PMC article.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
Casanova B, Lacruz L, Villar ML, Domínguez JA, Gadea MC, Gascón F, Mallada J, Hervás D, Simó-Castelló M, Álvarez-Cermeño JC, Calles C, Olascoaga J, Ramió-Torrentà L, Alcalá C, Cervelló A, Boscá I, Pérez-Mirallles FC, Coret F. Casanova B, et al. Neurol Sci. 2018 Aug;39(8):1423-1430. doi: 10.1007/s10072-018-3442-y. Epub 2018 Jun 7. Neurol Sci. 2018. PMID: 29882169
Cognitive Dysfunctions and Assessments in Multiple Sclerosis.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Oreja-Guevara C, et al. Front Neurol. 2019 Jun 4;10:581. doi: 10.3389/fneur.2019.00581. eCollection 2019. Front Neurol. 2019. PMID: 31214113 Free PMC article. Review.
Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions.
Muñoz-San Martín M, Reverter G, Robles-Cedeño R, Buxò M, Ortega FJ, Gómez I, Tomàs-Roig J, Celarain N, Villar LM, Perkal H, Fernández-Real JM, Quintana E, Ramió-Torrentà L. Muñoz-San Martín M, et al. J Neuroinflammation. 2019 Nov 14;16(1):220. doi: 10.1186/s12974-019-1590-5. J Neuroinflammation. 2019. PMID: 31727077 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
152 results